PTX secures EU Orphan Drug Designation for PTX-100 in CTCL

• PTX-100 is a first-in-class therapy designed to disrupt cancer growth pathways, now in Phase 2a trials for relapsed/refractory CTCL. • Complements existing U.S. FDA Orphan Drug and Fast Track status • Join CEO, James McDonnell, for an online investor briefing on Tuesday, 25th November at 3pm (AEDT). Register here: https://prescienttherapeutics.investorportal.com.au/investor- briefing/ MELBOURNE,